Purmorphamine Agonist
Purmorphamine Agonist - Related Videos
11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
0 Views •
Cited by 10 •
2011
A method for estimating the affinity constant of an agonist for the active state (Kb) of a G protein-coupled receptor is described. The analysis provides absolute or relative measures of Kb depending on whether constitutive receptor activation is measurable. Our method applies to various responses downstream from receptor activation.
01:24
Glucagon-like Receptor Agonists
0 Views •
2024
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP. GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:30
Adrenergic Agonists: Therapeutic Uses
0 Views •
2023
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies. Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension. Allergies and anaphylaxis:...
02:07
Stimulation of Dorsal Root Ganglion Sensory Neurons Using a Neuropeptide Receptor Agonist
0 Views •
2025
This video demonstrates the use of transfected dorsal root ganglion cells to study neurotransmitter release by stimulating them with a neuropeptide receptor agonist.
01:25
Drug-Receptor Interaction: Agonist
0 Views •
2025
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments. Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
FAQs
Purmorphamine can stimulate the pathway at the level of Smoothened, allowing Hedgehog signaling to proceed even when its normal ligand is not present. This makes it useful for separating effects caused by downstream pathway activation from effects that depend on supplying the ligand itself. The resulting GLI-dependent transcriptional response gives researchers a way to examine how pathway activity changes cellular behavior.
Smoothened serves as the membrane component that relays the activating signal, while GLI connects that signal to gene transcription. This division is experimentally important because changes in cell behavior can be interpreted in relation to pathway relay and transcriptional regulation rather than treated as an unexplained compound effect. The system therefore links molecular activation with developmental or tissue-level responses.
Controlled activation matters because Hedgehog signaling can influence pattern formation, tissue formation, and cell differentiation. By regulating purmorphamine exposure, researchers can investigate how pathway activity relates to particular developmental outcomes rather than observing only the unmanipulated system. This approach is especially relevant when comparing changes in stem-cell behavior, neural development, or tissue repair.
Unlike activation that depends on the pathway’s normal Hedgehog ligand, purmorphamine can promote signaling when that ligand is absent by acting through Smoothened. This distinction helps researchers test whether a developmental or cellular response is associated with Smoothened pathway activation itself. It also provides a way to study Hedgehog-related mechanisms under conditions where ligand availability would otherwise limit interpretation.
In stem-cell research, purmorphamine is used to examine whether Hedgehog pathway activation changes differentiation outcomes. The relevant outcomes include shifts in cell behavior and development, including effects associated with neural development. Such experiments connect a defined signaling intervention with the emergence of specialized cellular states, helping clarify how pathway activity contributes to developmental programs.
Studies of pattern formation use purmorphamine to investigate how activating Smoothened influences the organization and development of tissues. Because the compound can trigger GLI-dependent transcription without the usual ligand, researchers can focus on consequences of pathway activation while examining tissue-level changes. This makes it relevant to questions about how signaling controls spatial development and tissue formation.
Beyond basic development, purmorphamine supports research on tissue repair, disease, and developmental disorders. Its value in these settings comes from linking deliberate Hedgehog pathway activation with changes in cell behavior and tissue formation. Researchers can therefore investigate whether altered signaling contributes to a condition or whether pathway manipulation might inform regenerative medicine strategies, without treating the compound itself as a therapeutic outcome.